Background: Townsville (population=195,564, latitude=19.3°S) is the largest city in the Northern Queensland region of Australia, an area previously defined as a low/medium-prevalence zone for multiple sclerosis (MS). However, the epidemiology of MS in this region since 1981 is unknown.
Aims: To assess the 2012 to 2022 epidemiology of MS in Townsville.
Methods: Demographic/clinical data extracted from medical records of MS cases identified by public and private clinicians. Prevalence, and incidence and mortality rates estimated for 2012 and 2022 and age-standardised to the 2022 Australian population. Differences in estimates assessed by Poisson regression.
Results: Females and relapsing-remitting MS comprised most cases. The 2012 prevalence was 45.0/100,000 (50.4/100,000 age-standardised, F/M sex ratio=2.0). Prevalence increased by 188% in 2022, with a crude prevalence of 86.9/100,000 (91.7/100,000 age-standardised, F/M sex ratio=2.7). 2012-22 MS onset incidence rate was 3.8/100,000 person-years (age-standardised 3.5/100,000, F/M sex ratio=2.7). Mean age increased from 49.4 to 57.3 years. Age-standardised mortality rate was 0.9/100,000 person-years, with standardised mortality ratio=1.0.
Discussion: These results show that Townsville is a high-frequency region for MS, with prevalence and incidence on par with that seen at higher latitudes in Australia. These results have implications for clinical practice in the region and for organisational resource allocation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.msard.2023.104845 | DOI Listing |
J Med Life
November 2024
Department of Endocrinology, Diabetology and Nutrition, Mohammed VI University Hospital, Medical School, Mohamed the First University, Oujda, Morocco.
Non-functioning pituitary adenomas (NFPAs) are hormonally inactive benign tumors, usually diagnosed as macro-adenoma. The aim of our research was to analyze the clinical and hormonal characteristics of NFPAs using Knosp and revised Knosp classifications. Furthermore, we aimed to assess the possibility of predicting surgical remission after surgery.
View Article and Find Full Text PDFCirc Res
December 2024
Department of Biology and Genetics, McAllister Heart Institute, University of North Carolina, Chapel Hill. (W.S., J.P.-L., W.G.W., W.F.M., F.L.C.).
Background: Males and females exhibit distinct anatomic and functional characteristics of the heart, predisposing them to specific disease states.
Methods: We identified microRNA (miRNAs/miR) with sex-differential expression in mouse hearts.
Results: Four conserved miRNAs are present in a single locus on the X-chromosome and are expressed at higher levels in females than males.
J Acquir Immune Defic Syndr
January 2025
Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genoa.
Introduction: Few data are available about the forgiveness of two-drug (2DR) or low-barrier three-drug antiretroviral regimens. The aim of this study is to evaluate the real-life forgiveness of lamivudine/dolutegravir (3TC/DTG) and emtricitabine/tenofovir alafenamide/rilpivirine (FTC/TAF/RPV).
Methods: A two center retrospective observational study enrolled all people with HIV (PWH) treated with 3TC/DTG or FTC/TAF/RPV.
West Afr J Med
August 2024
Department of Medicine, Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria. Email: Tel: 08063241116.
Background/objective: Rheumatic diseases (RMDs) are among the leading health burdens and causes of disability globally. Interestingly, they are on the rise due to the increasingly ageing population. Inflammatory RMDs are not left behind in the rise, especially in Africa, where they were thought to be rare as there has been increasing reportage of these diseases in recent years.
View Article and Find Full Text PDFRespir Res
December 2024
Department of Research and Development, Ciro, Horn, The Netherlands.
Background: Pharmacological treatment is a cornerstone of chronic obstructive pulmonary disease (COPD) management, with general practitioners providing the most care. However, the lack of data on prescribing trends in initial pharmacotherapy in primary care hinders the understanding of how scientific and technical developments impact patient care and may also perpetuate suboptimal practices. Hence, this study aims to analyze trends in the initial pharmacological treatment of newly diagnosed COPD patients in Dutch primary care from 2010 to 2021.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!